Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Prepaid Assets: 2015-2025

Historic Prepaid Assets for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $59.8 million.

  • Intellia Therapeutics' Prepaid Assets rose 36.22% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year increase of 36.22%. This contributed to the annual value of $29.8 million for FY2024, which is 39.92% down from last year.
  • Per Intellia Therapeutics' latest filing, its Prepaid Assets stood at $59.8 million for Q3 2025, which was up 62.50% from $36.8 million recorded in Q2 2025.
  • Intellia Therapeutics' Prepaid Assets' 5-year high stood at $59.8 million during Q3 2025, with a 5-year trough of $14.0 million in Q3 2021.
  • Moreover, its 3-year median value for Prepaid Assets was $37.1 million (2025), whereas its average is $41.0 million.
  • Per our database at Business Quant, Intellia Therapeutics' Prepaid Assets skyrocketed by 222.72% in 2021 and then tumbled by 39.92% in 2024.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Prepaid Assets stood at $18.6 million in 2021, then grew by 9.81% to $20.4 million in 2022, then surged by 143.30% to $49.7 million in 2023, then tumbled by 39.92% to $29.8 million in 2024, then soared by 36.22% to $59.8 million in 2025.
  • Its Prepaid Assets was $59.8 million in Q3 2025, compared to $36.8 million in Q2 2025 and $37.1 million in Q1 2025.